[1]
|
Hinotsu, S., Akaza, H., Usami, M., Ogawa, O., Kagawa, S., Kitamura, T., Tsukamoto, T., Naito, S., Namiki, M., Hirao, Y., Murai, M. and Yamanaka, H. (2007) Current Status of Endocrine Therapy for Prostate Cancer in Japan Analysis of Primary Androgen Deprivation Therapy on the Basis of Data Collected by J-CaP. Japanese Journal of Clinical Oncology, 37, 775-781. https://doi.org/10.1093/jjco/hym098
|
[2]
|
de Bono, J.S., Logothetis, C.J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K.N., Jones, R.J., Goodman, O.B. Jr., Saad, F., Staffurth, J.N., Mainwaring, P., Harland, S., Flaig, T.W., Hutson, T.E., Cheng, T., Patterson, H., Hainsworth, J.D., Ryan, C.J., Sternberg, C.N., Ellard, S.L., Fléchon, A., Saleh, M., Scholz, M., Efstathiou, E., Zivi, A., Bianchini, D., Loriot, Y., Chieffo, N., Kheoh, T., Haqq, C.M. and Scher, H.I. (2011) Abiraterone and Increased Survival in Metastatic Prostate Cancer. The New England Journal of Medicine, 364, 1995-2005.
https://doi.org/10.1056/NEJMoa1014618
|
[3]
|
Ryan, C.J., Smith, M.R., de Bono, J.S., Molina, A., Logothetis, C.J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J.M., Ng, S., Carles, J., Mulders, P.F., Basch, E., Small, E.J., Saad, F., Schrijvers, D., Van Poppel, H., Mukherjee, S.D., Suttmann, H., Gerritsen, W.R., Flaig, T.W., George, D.J., Yu, E.Y., Efstathiou, E., Pantuck, A., Winquist, E., Higano, C.S., Taplin, M.E., Park, Y., Kheoh, T., Griffin, T., Scher, H.I. and Rathkopf, D.E. (2013) Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. The New England Journal of Medicine, 368, 138-148. https://doi.org/10.1056/NEJMoa1209096
|
[4]
|
Scher, H.I., Fizazi, K., Saad, F., Taplin, M.E., Sternberg, C.N., Miller, K., de Wit, R., Mulders, P., Chi, K.N., Shore, N.D., Armstrong, A.J., Flaig, T.W., Fléchon, A., Mainwaring, P., Fleming, M., Hainsworth, J.D., Hirmand, M., Selby, B., Seely, L. and de Bono, J.S. (2012) Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. The New England Journal of Medicine, 367, 1187-1197. https://doi.org/10.1056/NEJMoa1207506
|
[5]
|
Beer, T.M., Armstrong, A.J., Rathkopf, D.E., Loriot, Y., Sternberg, C.N., Higano, C.S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., Davis, I.D., de Bono, J.S., Evans, C.P., Fizazi, K., Joshua, A.M., Kim, C.S., Kimura, G., Mainwaring, P., Mansbach, H., Miller, K., Noonberg, S.B., Perabo, F., Phung, D., Saad, F., Scher, H.I., Taplin, M.E., Venner, P.M. and Tombal, B. (2014) Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. The New England Journal of Medicine, 371, 424-433. https://doi.org/10.1056/NEJMoa1405095
|
[6]
|
Tannock, I.F., de Wit, R., Berry, W.R., Horti, J., Pluzanska, A., Chi, K.N., Oudard, S., Théodore, C., James, N.D., Turesson, I., Rosenthal, M.A. and Eisenberger, M.A. (2004) Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. The New England Journal of Medicine, 351, 1502-1512.
https://doi.org/10.1056/NEJMoa040720
|
[7]
|
de Bono, J.S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M.J., Shen, L., Roessner, M., Gupta, S. and Sartor, A.O. (2010) Prednisone plus Cabazitaxel or Mitoxantrone for Metastatic Castration-Resistant Prostate Cancer Progressing after Docetaxel Treatment: A Randomised Open-Label Trial. The Lancet, 376, 1147-1154. https://doi.org/10.1016/S0140-6736(10)61389-X
|
[8]
|
Klotz, L., Boccon-Gibod, L., Shore, N.D., Andreou, C., Persson, B.E., Cantor, P., Jensen, J.K., Olesen, T. K. and Schr?der, F.H. (2008) The Efficacy and Safety of Degarelix: A 12-Month, Comparative, Randomized, Open-Label, Parallel-Group Phase III Study in Patients with Prostate Cancer. BJU International, 102, 1531-1538.
https://doi.org/10.1111/j.1464-410X.2008.08183.x
|
[9]
|
Tombal, B., Miller, K., Boccon-Gibod, L., Schr?der, F., Shore, N., Crawford, E.D., Moul, J., Jensen, J.K., Kold Olesen, T. and Persson, B.E. (2010) Additional Analysis of the Secondary End Point of Biochemical Recurrence Rate in a Phase 3 Trial (CS21) Comparing Degarelix 80 mg versus Leuprolide in Prostate Cancer Patients Segmented by Baseline Characteristics. European Urology, 57, 836-842. https://doi.org/10.1016/j.eururo.2009.11.029
|
[10]
|
Alexandra, M.L., Guy, L., Pedron, P., Bruyere, F., Rouprêt, M., Nsabimbona, B., Dahan, M., Hoffman, P., Salomon, L., Vordos, D., Hoznek, A., Le Corvoisier, P., Morel, P., Abbou, C. and de la Taille, A. (2013) A Switch from GnRH Agonist to GnRH Antagonist in Castration-Resistant Prostate Cancer Patients Leads to a Low Response Rate on PSA. World Journal of Urology, 31, 339-343. https://doi.org/10.1007/s00345-012-0841-1
|
[11]
|
de la Rosette, J., Davis 3rd, R., Frankel, D. and Kold Olsen, T. (2011) Efficacy and Safety of Androgen Deprivation Therapy after Switching from Monthly Leuprolide to Monthly Degarelix in Patients with Prostate Cancer. International Journal of Clinical Practice, 65, 559-566. https://doi.org/10.1111/j.1742-1241.2011.02637.x
|
[12]
|
Crawford, E.D., Tombal, B., Miller, K., Boccon-Gibod, L., Schr?der, F., Shore, N., Moul, J.W., Jensen, J.K., Olesen, T.K. and Persson, B.E. (2011) A Phase III Extension Trial with a 1-Arm Crossover from Leuprolide to Degarelix: Comparison of Gonadotropin-Releasing Hormone Agonist and Antagonist Effect on Prostate Cancer. The Journal of Urology, 186, 889-897. https://doi.org/10.1016/j.juro.2011.04.083
|
[13]
|
Radu, A., Pichon, C., Camparo, P., Antoine, M., Allory, Y., Couvelard, A., Fromont, G., Hai, M.T. and Ghinea, N. (2010) Expression of Follicle-Stimulating Hormone Receptor in Tumor Blood Vessels. The New England Journal of Medicine, 363, 1621-1630.
https://doi.org/10.1056/NEJMoa1001283
|
[14]
|
Porter, A.T., F.A.C.R.O. and Ben-Josef, E. (2001) Humoral Mechanisms in Prostate Cancer: A Role for FSH. Urologic Oncology, 6, 131-138.
https://doi.org/10.1016/S1078-1439(00)00124-1
|
[15]
|
Miller, K., Russel, C., Goble, S. and Persson, B.E. (2010) Open Label, Exploratory Study of Degarelix as Second-Line Hormonal Therapy in Patients with Prostate Cancer (CS27). European Urology Supplements, 9, 76. https://doi.org/10.1016/S1569-9056(10)60144-3
|
[16]
|
Morote, J., Orsola, A., Planas, J., Trilla, E., Raventós, C.X., Cecchini, L. and Catalán R. (2007) Redefining Clinically Significant Castration Levels in Patients with Prostate Cancer Receiving Continuous Androgen Deprivation Therapy. The Journal of Urology, 178, 1290-1295. https://doi.org/10.1016/j.juro.2007.05.129
|
[17]
|
Rove, K.O., Debruyne, F.M., Djavan, B., Gomella, L.G., Koul, H.K., Lucia, M.S., Petrylak, D.P., Shore, N.D., Stone, N.N. and Crawford, E.D. (2012) Role of Testosterone in Managing Advanced Prostate Cancer. Urology, 80, 754-762.
https://doi.org/10.1016/j.urology.2012.05.006
|
[18]
|
Fitzpatrick, J.M., Bellmunt, J., Fizazi, K., Heidenreich, A., Sternberg, C.N., Tombal, B., Alcaraz, A., Bahl, A., Bracarda, S., Di Lorenzo, G., Efstathiou, E., Finn, S.P., Foss?, S., Gillessen, S., Kellokumpu-Lehtinen, P.L., Lecouvet, F.E., Oudard, S., de Reijke, T.M., Robson, C.N., De Santis, M., Seruga, B. and de Wit, R. (2014) Optimal Management of Metastatic Castration-Resistant Prostate Cancer: Highlights from a European Expert Consensus Panel. European Journal of Cancer, 50, 1617-1627. https://doi.org/10.1016/j.ejca.2014.03.010
|